Who We Are
RadioMedix is a cutting-edge radiopharmaceutical oncology company leading the charge in the development and commercialization of targeted alpha and beta therapies, as well as next-generation diagnostic imaging agents. With deep expertise spanning early-stage R&D to commercial-scale GMP manufacturing, we specialize in harnessing the power of isotopes like Ac-225, Lu-177, Pb-212, Pb 203, and Ga-68 to treat and diagnose some of the toughest cancers.
From concept to clinic, RadioMedix is driven by science, powered by precision, and committed to patient impact. Whether it’s building robust CDMO partnerships or advancing our own pipeline, we move fast, think big, and aim to disrupt—not follow—the standard of care.
